TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs

I-Mab's Broad and Innovative Pipeline to Leverage TRACON's U.S. Product Development Solution Platform SHANGHAI, Nov. 29, 2018 -- (Healthcare Sales & Marketing Network) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical compan... Biopharmaceuticals, Oncology I-Mab Biopharma, TRACON Pharmaceuticals, immuno-oncology
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news